Merck & Co., Inc. (MRK)
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc MRK, to review Gardasil's performance and future outlook in China.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.
Should You Pick Merck Stock At $115 After A Q2 Beat?
Merck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates. The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2.20, respectively.
Merck reports earlier-than-expected improvement in semiconductor market
Merck KGaA is seeing a faster-than-expected improvement in its semiconductor materials business, the German pharma and technology company said on Thursday.
Merck Analysts Slash Their Forecasts After Q2 Results
Merck & Co Inc MRK reported better-than-expected second-quarter earnings and sales results on Tuesday.
S&P 500 Gains and Losses Today: Merck Stock Plunges on Guidance Cut
Major U.S. equities indexes were mixed for the second straight day as tech stocks lost ground ahead of key earnings reports and a decision on interest rates from the Federal Reserve.
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Umer Raffat - Evercore Carter Gould - Barclays Tim Anderson - Wolfe Research Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Dana Graybosch - Leerink Akash Tewari - Jefferies Trung Huynh - UBS Louise Chen - Cantor Chris Shibutani - Goldman Sachs Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Co. Q2 Sales and Earnings Conference Call [Operator Instructions].
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
Merck Stock Slides on Lowered Adjusted EPS Guidance
Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast.
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
